daratumumab

AssetAlso called 3003-005, HuMax-CD38, Darzalex

Anti-CD38 monoclonal antibody inducing targeted immune-mediated lysis of CD38-expressing cells.

Stage
Approved
Modality
Antibody
Target
CD38
16
Indications
290
Trials
1
Developer

Approved by the FDA on Nov 16, 2015 (BLA761036). 2 approvals stand. FDA

Indications

16
  • Multiple myeloma

    Approved, FDA

  • Newly diagnosed multiple myeloma

    Approved, EMA

  • Relapsed and refractory multiple myeloma

    Approved, EMA

13 more

In the full profile

  • Target and mechanism1
  • Owner and partners1
  • Trials290
  • Evidence for its targets2
  • Competitors12
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets